0000000001034126

AUTHOR

Antoinette Maassen Van Den Brink

0000-0001-7176-126x

showing 1 related works from this author

Blocking CGRP in migraine patients – a review of pros and cons

2017

Abstract Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and epilepsy. During the last decade, however, blocking calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for prevention of migraine attacks. CGRP has been shown to be released during migraine attacks and it may play a causative role in induction of migraine attacks. Here, we review the pros and cons of blocking CGRP in migraine patients. To date, two different classes of drugs blocking CGRP have been developed: …

0301 basic medicinemedicine.medical_specialtyanesthesiology and pain medicineNeurologyCalcitonin Gene-Related PeptideMigraine DisordersCentral nervous systemlcsh:MedicineNeurological disorderReview ArticleCalcitonin gene-related peptidePlaceboBioinformatics03 medical and health sciencesEpilepsy0302 clinical medicineCalcitonin Gene-Related Peptide Receptor AntagonistsMedicineAnimalsHumansMigraineneurology (clinical)integumentary systembusiness.industrylcsh:Racute treatment; CGRP; CGRP receptor; gepants; migraine; prophylactic treatment; neurology (clinical); anesthesiology and pain medicineCgrp receptorGeneral MedicineGepantsmedicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureMigrainenervous systemAnesthesiaAcute treatment; Cgrp; Cgrp receptor; Gepants; Migraine; Prophylactic treatment; Neurology (clinical); Anesthesiology and Pain MedicineCgrpAnimal studiesbusinessGepantProphylactic treatmentAcute treatment030217 neurology & neurosurgery
researchProduct